Hyman Charles D Becton Dickinson & CO Transaction History

Hyman Charles D

$1.79 Billion
Q2 2024

A detailed history of Hyman Charles D transactions in Becton Dickinson & CO stock. As of the latest transaction made, Hyman Charles D holds 2,550 shares of BDX stock, worth $574,897. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,550

Previous 2,554 0.16%

Holding current value

$574,897

Previous $631,000 5.71%

% of portfolio

0.03%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$225.07 - $246.17 $900 - $984	-4 Reduced 0.16%	2,550 $595,000
Q4 2023 Feb 06, 2024	BUY	$232.24 - $267.23 $31,120 - $35,808	134 Added 5.54%	2,554 $622,000
Q1 2023 May 04, 2023	BUY	$229.71 - $259.35 $57,427 - $64,837	250 Added 11.52%	2,420 $599,000
Q4 2022 Feb 06, 2023	SELL	$218.29 - $256.91 $53,699 - $63,199	-246 Reduced 10.18%	2,170 $552,000
Q3 2020 Oct 26, 2020	SELL	$215.77 - $276.76 $4,962 - $6,365	-23 Reduced 0.94%	2,416 $562,000
Q4 2019 Feb 03, 2020	BUY	$236.45 - $266.82 $5,438 - $6,136	23 Added 0.95%	2,439 $663,000
Q3 2019 Nov 07, 2019	SELL	$230.58 - $256.08 $8,762 - $9,731	-38 Reduced 1.55%	2,416 $611,000
Q1 2019 May 13, 2019	SELL	$206.05 - $248.17 $106,321 - $128,055	-516 Reduced 17.37%	2,454 $613,000
Q2 2018 Aug 06, 2018	SELL	$208.1 - $233.85 $6,034 - $6,781	-29 Reduced 0.97%	2,970 $711,000
Q1 2018 May 07, 2018	SELL	$205.46 - $240.27 $205 - $240	-1 Reduced 0.03%	2,999 $650,000
Q4 2017 Feb 06, 2018	BUY	$189.0 - $222.64 $12,852 - $15,139	68 Added 2.32%	3,000 $642,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,932	2,932 $572,000

Others Institutions Holding BDX

# of Institutions

1,737

Shares Held

250M

Call Options Held

690K

Put Options Held

787K

View Full List

About BECTON DICKINSON & CO

Ticker BDX
Exchange NYSE
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 285,195,008
Market Cap $64.3B
Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenou...

More about BDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hyman Charles D, based on Form 13F filings with the SEC.

News

Stay updated on Hyman Charles D with notifications on news.

Account